| Title: |
Addition of daptomycin for the treatment of pneumococcal meningitis: protocol for the AddaMAP study |
| Authors: |
Chavanet, Pascal; Fournel, Isabelle; Bourredjem, Abderrahmane; Piroth, Lionel; Blot, Mathieu; Sixt, Thibault; Binquet, Christine |
| Publisher Information: |
BMJ Publishing Group Ltd |
| Publication Year: |
2023 |
| Collection: |
HighWire Press (Stanford University) |
| Subject Terms: |
Infectious diseases |
| Description: |
Background The leading cause of acute bacterial meningitis in adults is Streptococcus pneumoniae . This infection is associated with high rates of mortality and morbidity related, among other factors, to the excessive host response to the pneumococcal lysis. Experimental in vitro and in vivo data show that the combination of corticosteroids/third-generation cephalosporins and the non-lytic antibiotic, daptomycin, has synergistic effects with (1) a rapid cerebrospinal fluid sterilisation, (2) less brain damages and (3) less loss of cognitive performances. Despite these encouraging results, daptomycin has never been evaluated in adult patients with pneumococcal meningitis. Methods and analysis The AddaMAP trial is a phase II, open-label, Simon’s two-stage, multicentre trial that has been designed to assess the efficacy and safety of adding daptomycin (10 mg/kg/d for 8 days) to the recommended treatment (corticosteroids+third generation cephalosporin) in adults with confirmed pneumococcal meningitis. The main endpoint is the disability-free survival (defined as modified Rankin Scale mRS≤2) at day 30. Secondary outcomes are overall mortality, disability at D30 and D90 (mRS, Glasgow Coma Scale and Glasgow Outcome Scales, mini-mental score), hearing loss (Hearing Handicap Inventory Test at D30 and D90, routine audiometric test and Hearing-it test at D30), and quality of life (12-item Short Form Survey and WHO QOL BREF). Seventy-two analysable patients are required. Ethics and dissemination The study protocol was approved by the Institutional Review Board of the IDF 1 of the ethics committee on 16 January 2018, and authorisation was obtained from the Agence Nationale de Securit e ´ des M e ´ dicaments et des Produits de Sant e ´ on 22 September 2017. The results will be submitted for publication in a peer-reviewed journal. Trial registration number NCT03480191 . |
| Document Type: |
text |
| File Description: |
text/html |
| Language: |
English |
| Relation: |
http://bmjopen.bmj.com/cgi/content/short/13/7/e073032; http://dx.doi.org/10.1136/bmjopen-2023-073032 |
| DOI: |
10.1136/bmjopen-2023-073032 |
| Availability: |
http://bmjopen.bmj.com/cgi/content/short/13/7/e073032; https://doi.org/10.1136/bmjopen-2023-073032 |
| Rights: |
Copyright (C) 2023, British Medical Journal Publishing Group |
| Accession Number: |
edsbas.1E69E05 |
| Database: |
BASE |